Ahmedabad, India – November 2024 – Intas Pharmaceuticals is thrilled to welcome Arun R Hegde as the new Vice President of Sales & Marketing, Oncology. With a robust experience spanning over 30 years in the pharmaceutical industry, Arun brings an exceptional background in managing oncology business units, formulating strategic market access initiatives, overseeing key account management, and driving P&L success.
Arun most recently served as the Business Unit Director – Oncology at Merck Sharp & Dohme Indonesia. In this role, he led the oncology division and established key strategic initiatives in Indonesia’s healthcare market, strengthening MSD’s oncology presence over his tenure of more than a year.
Before his role at MSD Indonesia, Arun was the Business Unit Director – Oncology at MSD Pharmaceuticals Private Limited in India. With a focus on oncology, he managed sales, contract negotiations, and healthcare solutions, driving significant market impact across India. His leadership at MSD spanned over six years, making notable strides in advancing the company’s oncology portfolio.
Earlier, Arun held the role of Associate Vice President – Oncology at Mylan Pharmaceuticals Private Limited in Bangalore. During his tenure, he launched and established the brand Hertraz, securing a strong market position and propelling Mylan to the Top 10 MNCs in oncology within 18 months.
Arun’s career also includes his position as Senior General Manager – Sales and Marketing at Mylan Pharmaceuticals – Onco Care Division, where he played a critical role in launching Mylan’s oncology division, introducing cutting-edge therapies in India. His contributions significantly expanded Mylan’s footprint in the oncology space.
Arun’s foundational experience includes his impactful tenure at Dr. Reddy’s Laboratories, where he served as Associate Director – Oncology India. Here, he championed the brand Reditux, leading it to a No.1 position in the segment, and developed a strong business presence in the onco-hematology market.
About Intas Pharmaceuticals
Intas Pharmaceuticals is a leading multinational pharmaceutical formulation development, manufacturing, and marketing organization, with a Compound Annual Growth Rate (CAGR) of 19% and annual revenue surpassing $2.5 billion. Established as a privately-owned Indian pharmaceutical leader, Intas operates in 85+ countries, with over 70% of its revenue sourced internationally under the brand name Accord Healthcare across regions such as the EU, US, Canada, South America, Australia, and Asia.
Currently ranked 6th in the Indian pharmaceutical market, Intas has established a strong presence across major therapeutic segments, including oncology, CNS, cardiology, and diabetes. With a mission focused on affordability and access, Intas’ biopharma division champions “Biosimilars for Billions” in fields like oncology, autoimmune diseases, and nephrology. The company operates 16 state-of-the-art R&D and manufacturing facilities, with 10 in India and additional facilities across the UK, Mexico, and Greece.
Read Also : Cultivating Safe Spaces: The Strategic Role of L&D in Workplace Well-being
